Social Anxiety Disorder (SAD/Social Phobia) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Social Anxiety Disorder (SAD/Social Phobia) Clinical Trials Market Report Overview
The social anxiety disorder (SAD/social phobia) trial market research report provides an overview of the social anxiety disorder (SAD/social phobia) trials scenario. The report provides top-line data relating to the clinical trials on social anxiety disorder. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Key Regions | · North America
· Asia-Pacific · Europe · Middle East and Africa · South and Central America |
Key Countries | · The US
· Canada · United Kingdom · Japan · Germany · France · Italy |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · GSK plc
· The Lundbeck Foundation · Viatris Inc · VistaGen Therapeutics Inc · Johnson & Johnson · Others |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
SAD Trials Market Segmentation by Regions and Countries
The key regions in the Social Anxiety Disorder (SAD/Social Phobia) trials market are North America, Asia-Pacific, Europe, Middle East and Africa, and South and Central America. North America led with more than 30% of the clinical trials conducted as of August 2023.
In a country-wise analysis, as of August 2023, the US had the highest number of SAD trials, followed by Canada, Russia, Iran China, South Korea, the United Kingdom, Japan, Germany, and Spain.
G7 countries: Among the G7 (United States, United Kingdom, Germany, Canada, Japan, France, and Italy) countries, Canada had the highest proportion of SAD to central nervous system clinical trials as of August 2023. Moreover, out of all the SAD clinical trials conducted in the G7 countries, the majority were in the US.
E7 countries: Among the E7 (China, India, Russia, Turkey, Brazil, Mexico, and Indonesia) countries, Russia had the highest proportion of SAD to Central Nervous System clinical trials as of August 2023. Also, out of all the SAD clinical trials conducted in the E7 countries, the majority were in Russia.
SAD Trials Analysis by Regions, 2023 (%)
Buy Full Report to Get More Regional Insights into the SAD Trials Market or,
SAD Trials Market Segmentation by Sponsor Types
The key sponsor types in the SAD trials market are company, institution, and the government. In August 2023, the company sponsor type dominated the SAD trials market share, followed by the institution.
SAD Trials Market Analysis by Sponsor Types, 2023 (%)
Buy Full Report to Get More Sponsor Type Insights into the SAD Trials Market or,
SAD Trials Market - Competitive Landscape
The leading sponsors in the SAD trials market are GSK plc, the Lundbeck Foundation, Viatris Inc, VistaGen Therapeutics Inc, Johnson & Johnson, and others. In 2023, GSK plc has conducted the highest number of SAD trials.
SAD Trials Market Analysis by Sponsors, 2023 (%)
Buy Full Report to Know More About the Leading Players in the SAD Trials Market or,
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies concerning investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
The Lundbeck Foundation
Viatris Inc
Johnson & Johnson
VistaGen Therapeutics Inc
Novartis AG
Pfizer Inc
AbbVie Inc
AstraZeneca Plc
Aurobindo Pharma Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
Which was the dominating region in the SAD/social phobia trials market?
North America was the dominating region in the SAD/social phobia trials market as of August 2023.
-
Which country was contributing the highest number from the G7 countries in the SAD/social phobia trials?
Canada accounted for the highest number of SAD/social phobia trials as of August 2023.
-
Which sponsor type was the most prominent in the Social Anxiety Disorder (SAD/social phobia) trials market?
The company sponsor type led the SAD/social phobia trials market.
-
Who are the leading sponsors in the SAD/social phobia trials market?
The leading sponsors in the SAD/social phobia trials market are GSK Plc, Lundbeck Foundation, Viatris Inc, VistaGen Therapeutics Inc, Johnson & Johnson, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.